A5002284163- Coronary Interventions and Diagnostics
- Cardiac Valve Diseases and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Peripheral Artery Disease Management
- Cerebrovascular and Carotid Artery Diseases
- Aortic aneurysm repair treatments
- Infective Endocarditis Diagnosis and Management
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Atrial Fibrillation Management and Outcomes
- Statistical Methods in Clinical Trials
- Cardiac, Anesthesia and Surgical Outcomes
Haga Hospital
2016-2024
University of Twente
2022
Medisch Spectrum Twente
2022
Isala
2012-2014
Background Quantitative flow ratio ( QFR ) is a novel modality for physiological lesion assessment based on 3‐dimensional vessel reconstructions and contrast velocity estimates. We evaluated the value of online during routine invasive coronary angiography procedural feasibility, diagnostic performance, agreement with pressure‐wire–derived fractional reserve FFR as gold standard in an international multicenter study. Methods Results FAVOR II E‐J (Functional Assessment by Various Flow...
The aim of this study was to assess 2-year safety and efficacy the current-generation thin composite-wire-strut durable-polymer Resolute Onyx zotarolimus-eluting stent (ZES), compared with ultrathin-strut biodegradable-polymer Orsiro sirolimus-eluting (SES) in all-comers a pre-specified small-vessel subgroup analysis. ZES is widely used clinical practice, but no follow-up data beyond 1 year have been published. randomized BIONYX (Bioresorbable Polymer-Coated Versus Durable Stents) trial...
Background In a previous trial, higher 5-year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus-eluting stents (SES). We assessed safety and efficacy of all-comers as well patients diabetes treated SES or Synergy everolimus-eluting (EES) versus durable Resolute Integrity zotarolimus-eluting (ZES). Methods Results The randomized BIO-RESORT (Comparison Biodegradable Polymer Durable Drug-Eluting Stents in an All Comers Population) trial enrolled 3514...
Patients with severe aortic stenosis (AS) frequently present concomitant obstructive coronary artery disease (CAD). In those, current guidelines recommend combined bypass grafting (CABG) and surgical valve replacement (SAVR) as the preferred treatment option, although this approach is associated a high rate of clinical events. Combined transcatheter implantation (TAVI) percutaneous intervention (PCI) or without FFR have evolved valid alternative for cardiac surgery in patients AS multivessel...
BACKGROUND: Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim this study was to compare effectiveness biodegradable-polymer sirolimus-eluting with durable-polymer zotarolimus-eluting receiving 1 month PCI. METHODS: Bioflow-DAPT Study international, randomized, open-label trial conducted 52...
Abstract Background The use and clinical outcomes of fractional flow reserve (FFR)–guided revascularization in patients presenting with either stable coronary artery disease (CAD) or an acute syndrome (ACS) daily practice are uncertain. Objective To prospectively characterize the frequency change treatment plan when FFR is performed compared to initial decision based on angiography alone procedure‐related outcomes. Methods We undertook a prospective, multicenter, multinational, open‐label,...
Abstract Objectives To compare 2‐year outcome following treatment with drug‐eluting stents (DES) for acute myocardial infarction (MI) versus non‐MI clinical syndromes. In MI patients, a stent‐level comparison was performed, comparing Resolute Onyx Orsiro stents. Background patients presenting MI, higher adverse event rates have been reported. So far, no results >1 year published of treated Onyx. Methods This post‐hoc analysis the randomized BIONYX trial( NCT02508714 ) assessed main target...
<title>Abstract</title> <bold>Background</bold> Despite advancements in secondary cardiovascular prevention, individuals with chronic coronary syndrome (CCS) still experience a lingering risk of adverse ischemic events. To minimize this residual by stabilizing and regressing the disease process, there is consensus that antithrombotic therapy crucial role for prevention. The combination low-dose rivaroxaban (2.5mg BID) aspirin, known as dual-pathway inhibition, has emerged strategy to...
Purpose: No early safety and efficacy trials including the second generation Zotarolimus (Endeavor®) Everolimus (Xience V®) coated stents were performed in elective PCI patients. Within STRESSED (direct Stenting To Reduce REStenosis Stent Era with Drug elution) trial a sub analysis was comparing incidence of restenosis clinical outcome both stents. Methods: total 600 patients stable or unstable angina pectoris recent (<30 days) myocardial infarction randomized to different revascularisation...